These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. An erythropoietin autocrine/paracrine axis modulates the growth and survival of human prostate cancer cells. Jeong JY; Hoxhaj G; Socha AL; Sytkowski AJ; Feldman L Mol Cancer Res; 2009 Jul; 7(7):1150-7. PubMed ID: 19567780 [TBL] [Abstract][Full Text] [Related]
29. Erythropoietin and its lost receptor. Sturiale A; Campo S; Crascì E; Coppolino G; Bolignano D; Grasso G; Buemi M Nephrol Dial Transplant; 2007 May; 22(5):1484-5. PubMed ID: 17267537 [No Abstract] [Full Text] [Related]
30. [Erythropoietin]. Jin XC Sheng Li Ke Xue Jin Zhan; 1995 Jan; 26(1):73-6. PubMed ID: 7604230 [No Abstract] [Full Text] [Related]
36. A few specialty drug prices fall--all generics. Manag Care; 2008 Dec; 17(12):46. PubMed ID: 19127766 [No Abstract] [Full Text] [Related]
37. Staving off death: a case study of the pharmaceutical industry's strategies to protect blockbuster franchises. Gorlin DI Food Drug Law J; 2008; 63(4):823-64. PubMed ID: 19601385 [No Abstract] [Full Text] [Related]
38. White paper. The five myths of generic competition. A Pharma Matters report. March 2009. Drug News Perspect; 2009 Apr; 22(3):171-5. PubMed ID: 19440560 [TBL] [Abstract][Full Text] [Related]
39. The economics of pediatric formulation development for off-patent drugs. Milne CP; Bruss JB Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801 [TBL] [Abstract][Full Text] [Related]
40. Market watch: Sales of biologics to show robust growth through to 2013. Goodman M Nat Rev Drug Discov; 2009 Nov; 8(11):837. PubMed ID: 19876035 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]